Alnylam Pharmaceuticals Inc. (ALNY)
Symbol Info
Listed Symbol ALNY
Name Alnylam Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $74,908,000
Latest Fiscal EPS $-7.56
Price Info
21 Day Moving Average $79.9229
21 Day EMA $80.356410
50 Day Moving Average $81.3496
50 Day EMA $80.070010
200 Day EMA $81.022540
200 Day Moving Average 79.757800
52 Week High $96.08
52 Week Low $60.27
52 Week Change $7.876300
Alpha -0.005307
Beta 2.3466
Standard Deviation 0.156719
R2 0.264421
Periods 60
Share Information
10 Day Average Volume 528,302
20 Day Average Volume 601,010
30 Day Average Volume 662,360
50 Day Average Volume 679,638
Outstanding Shares 111,207,651
Float Shares 110,669,994
Percent Float 99.52%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 708
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 10,324,204
Institute Holdings Percent -
Institute Sold Previous 3 Months 5,697,751
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 42
Insider Holdings Percent 0.50%
Insider Sold Previous 3 Months -
Insiders Shares Owned 537,657
Price Change
7 Day Price Change $5.8099976
7 Day Percent Change 7.36%
21 Day Price Change $3.6800003
21 Day Percent Change 4.54%
30 Day Price Change $-0.7099991
30 Day Percent Change -0.83%
Month To Date Price Change $4.3600
Month To Date Percent 5.42%
90 Day Price Change $8.889999
90 Day Percent Change 11.71%
Quarter To Date $4.360001
Quarter To Date Percent 5.42%
180 Day Price Change $2.709999
180 Day Percent Change 3.30%
200 Day Price Change $-7.050003
200 Day Percent Change -7.68%
Year To Date $11.869995
Year To Date Percent 16.28%
Profile
Description Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis, Alnylam has partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Details
Issue Type CS
Market Cap $9,428,184,652
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 111,207,651
CEO John M. Maraganore
Employees 1,065
Last Audit UE
Classification
CIK 0001178670
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 300 Third Street
3rd Floor
Cambridge, MA 2142
Website http://www.alnylam.com
Facisimile +1 617 551-8101
Telephone +1 617 551-8200
Email
Key Ratios
Profitability
EBIT Margin -890.1
EBITDA Margin -867.4
Pre-Tax Profit Margin -785.8
Profit Margin Cont -
Gross Margin 90.60
Profit Margin TOT -
Income Statements
Revenue $99,041,000
Revenue Per Share $0.8906
Revenue 3 Years $27.13
Revenue 5 Years $17.29
Valuation Measures
PE Ratio -
Enterprise Value $7,353,046,293
Price To Sales 95.194760
Price To Free Cash -55
PE High Last 5 Years -
Price To Book 4.8
Price To Cash Flow 11.1
PE Low Last 5 Years -
Price To Tangible Book 4.8
Financial Strength
Total Debt To Equity 0.2
Int Coverage -
Current Ratio 6.3
Leverage Ratio 1.5
Quick Ratio 6.0
Long Term Debt To Capital 0.15
Assets
Receivables Turnover 1.6
Invoice Turnover 0.40
Assets Turnover -
Management Effectiveness
Return Assets -38.09
Return On Equity -50.81
Return On Capital -47.26
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ALNY
Alnylam Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.